Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 112

1.

Mirtazapine, and mirtazapine-like compounds as possible pharmacotherapy for substance abuse disorders: evidence from the bench and the bedside.

Graves SM, Rafeyan R, Watts J, Napier TC.

Pharmacol Ther. 2012 Dec;136(3):343-53. doi: 10.1016/j.pharmthera.2012.08.013. Epub 2012 Aug 29. Review.

2.

Mirtazapine enhances frontocortical dopaminergic and corticolimbic adrenergic, but not serotonergic, transmission by blockade of alpha2-adrenergic and serotonin2C receptors: a comparison with citalopram.

Millan MJ, Gobert A, Rivet JM, Adhumeau-Auclair A, Cussac D, Newman-Tancredi A, Dekeyne A, Nicolas JP, Lejeune F.

Eur J Neurosci. 2000 Mar;12(3):1079-95.

PMID:
10762339
3.

Mirtazapine alters cue-associated methamphetamine seeking in rats.

Graves SM, Napier TC.

Biol Psychiatry. 2011 Feb 1;69(3):275-81. doi: 10.1016/j.biopsych.2010.09.032. Epub 2010 Nov 20.

4.

The pharmacologic profile of mirtazapine.

de Boer T.

J Clin Psychiatry. 1996;57 Suppl 4:19-25. Review.

PMID:
8636062
5.

Acute and long-term actions of the antidepressant drug mirtazapine on central 5-HT neurotransmission.

Haddjeri N, Blier P, de Montigny C.

J Affect Disord. 1998 Dec;51(3):255-66.

PMID:
10333981
6.

Discriminative stimulus properties of the atypical antidepressant, mirtazapine, in rats: a pharmacological characterization.

Dekeyne A, Millan MJ.

Psychopharmacology (Berl). 2009 Apr;203(2):329-41. doi: 10.1007/s00213-008-1259-8. Epub 2008 Aug 16.

PMID:
18709360
7.

A placebo-controlled trial of mirtazapine for the management of methamphetamine withdrawal.

Cruickshank CC, Montebello ME, Dyer KR, Quigley A, Blaszczyk J, Tomkins S, Shand D.

Drug Alcohol Rev. 2008 May;27(3):326-33. doi: 10.1080/09595230801935672.

PMID:
18368615
8.

Noradrenergic modulation of central serotonergic neurotransmission: acute and long-term actions of mirtazapine.

Haddjeri N, Blier P, de Montigny C.

Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:11-7. Review. Erratum in: Int Clin Psychopharmacol 1996 Jun;11(2):153.

PMID:
8930005
9.

Mirtazapine: clinical overview.

Gorman JM.

J Clin Psychiatry. 1999;60 Suppl 17:9-13; discussion 46-8. Review.

10.

The effects of mirtazapine on central noradrenergic and serotonergic neurotransmission.

de Boer T.

Int Clin Psychopharmacol. 1995 Dec;10 Suppl 4:19-23. Review. Erratum in: Int Clin Psychopharmacol 1996 Jun;11(2):153.

PMID:
8930006
11.

A risk-benefit assessment of mirtazapine in the treatment of depression.

Kasper S, Praschak-Rieder N, Tauscher J, Wolf R.

Drug Saf. 1997 Oct;17(4):251-64. Review. Erratum in: Drug Saf 1998 Feb;18(2):123.

PMID:
9352961
12.

A review of the pharmacological and clinical profile of mirtazapine.

Anttila SA, Leinonen EV.

CNS Drug Rev. 2001 Fall;7(3):249-64. Review.

13.

The atypical antidepressant mirtazapine attenuates expression of morphine-induced place preference and motor sensitization.

Graves SM, Persons AL, Riddle JL, Napier TC.

Brain Res. 2012 Sep 7;1472:45-53. doi: 10.1016/j.brainres.2012.07.007. Epub 2012 Jul 20.

14.

The use of mirtazapine in a patient with chronic pain.

Brannon GE, Stone KD.

J Pain Symptom Manage. 1999 Nov;18(5):382-5.

PMID:
10584463
16.

Mirtazapine: a review of its use in major depression and other psychiatric disorders.

Croom KF, Perry CM, Plosker GL.

CNS Drugs. 2009;23(5):427-52. doi: 10.2165/00023210-200923050-00006. Review.

PMID:
19453203
17.

Repeated mirtazapine nullifies the maintenance of previously established methamphetamine-induced conditioned place preference in rats.

Voigt RM, Mickiewicz AL, Napier TC.

Behav Brain Res. 2011 Nov 20;225(1):91-6. doi: 10.1016/j.bbr.2011.07.009. Epub 2011 Jul 12.

18.

Mirtazapine treatment after conditioning with methamphetamine alters subsequent expression of place preference.

Herrold AA, Shen F, Graham MP, Harper LK, Specio SE, Tedford CE, Napier TC.

Drug Alcohol Depend. 2009 Jan 1;99(1-3):231-9. doi: 10.1016/j.drugalcdep.2008.08.005. Epub 2008 Oct 21.

PMID:
18945553
19.

Suppressive effect of mirtazapine on the HPA system in acutely depressed women seems to be transient and not related to antidepressant action.

Horstmann S, Dose T, Lucae S, Kloiber S, Menke A, Hennings J, Spieler D, Uhr M, Holsboer F, Ising M.

Psychoneuroendocrinology. 2009 Feb;34(2):238-48. doi: 10.1016/j.psyneuen.2008.09.004. Epub 2008 Oct 15.

PMID:
18926641
20.

Pharmacology of rapid-onset antidepressant treatment strategies.

Blier P.

J Clin Psychiatry. 2001;62 Suppl 15:12-7. Review.

Supplemental Content

Support Center